Replies to post #18072 on Momenta Pharmaceuticals, Inc. (MNTA)

[alternatepatel]

depressing.

[jbog]

says Momenta is planning for a 2018 2H launch however potential remains for 1H.

Also Sandoz is considering alternative fill/finish contractor if necessary.

If the 40mg drug follows the same path as the 20mg release there will be no profitable patients available by 2018 2H so as normal, Momenta/Sandoz has wasted this opportunity.

It's refreshing to see that Sandoz now has concerns.

[jbog]

mouton,

After a quick read of the SEC document it looks like Momenta is all but waving the white flag pertaining to the future profitability of Copaxone, 20mg or 40mg.

What a shame.



Who would have ever expected this???